stoxline Quote Chart Rank Option Currency Glossary
  
Serina Therapeutics Inc (SER)
8.24  -2.31 (-21.9%)    06-21 16:00
Open: 11.31
High: 11.31
Volume: 77,835
  
Pre. Close: 10.55
Low: 8.0301
Market Cap: 69(M)
Technical analysis
2024-06-21 4:55:13 PM
Short term     
Mid term     
Targets 6-month :  14.02 1-year :  17.01
Resists First :  12 Second :  14.56
Pivot price 10.06
Supports First :  7.86 Second :  6.53
MAs MA(5) :  10.84 MA(20) :  9.94
MA(100) :  11.67 MA(250) :  17.78
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  25.9 D(3) :  52.4
RSI RSI(14): 41
52-week High :  35.71 Low :  7.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SER ] has closed above bottom band by 6.9%. Bollinger Bands are 10.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.33 - 11.4 11.4 - 11.45
Low: 7.91 - 7.98 7.98 - 8.03
Close: 8.15 - 8.25 8.25 - 8.32
Company Description

Headline News

Wed, 15 May 2024
Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse ... - GlobeNewswire

Tue, 14 May 2024
Serina Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com

Mon, 01 Apr 2024
Serina Therapeutics: Strategic Restructuring and Merger Success - TipRanks.com - TipRanks

Wed, 27 Mar 2024
Serina completes AgeX merger, targets neurological diseases and pain - Longevity.Technology

Tue, 26 Mar 2024
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics - GlobeNewswire

Mon, 20 Nov 2023
Pfizer licenses small molecule drug delivery technology from Serina - Pharmaceutical Technology

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Industry:
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android